TScan Therapeutics, Qiagen to Develop T-Cell Test for Covid-19 Immune Response
The covid-19 laboratory tests will use discoveries from TScan’s high-throughput TCR/Target discovery platform, T-Scan.
Read MorePosted by Melanie Hamilton-Basich | Nov 16, 2020 | Covid 19 |
The covid-19 laboratory tests will use discoveries from TScan’s high-throughput TCR/Target discovery platform, T-Scan.
Read MorePosted by Laurie Bonner | Nov 16, 2020 | Compliance, Covid 19 |
The changes make it easier to navigate to questions by topic.
Read MorePosted by Melanie Hamilton-Basich | Nov 13, 2020 | Covid 19 |
Testing of clinical samples has shown the QiaReach SARS-CoV-2 Antigen Test to have a sensitivity of 90% and a specificity of 100%.
Read MorePosted by Melanie Hamilton-Basich | Nov 13, 2020 | Covid 19 |
The contract enables InBios to ramp up production of the covid-19 tests to 400,000 units per week – 20 times the facility’s current output – by May 2021.
Read MorePosted by Melanie Hamilton-Basich | Nov 13, 2020 | Biochemicals & Chemical Reagents, Covid 19, Labwear & Consumables |
Laboratories are having to limit other types of testing because they only have so many supplies, and covid-19 testing is taking priority.
Read More